ASCENT is a multicenter, open-label, randomized, phase 3 study in patients with metastatic triple negative breast cancer (TNBC) refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Learn about eligibility requirements for the ASCENT trial.
Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization. Learn more about the ASCENT trial design.
Outcome measures include: progression-free survival, overall survival, objective response rate, duration of response, and time to onset of response. See full information about outcome measures.
For questions or more information about the ASCENT Trial, please contact us.
Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization from 1 of the 4 allowed regimens. Subjects will be treated until progression, unacceptable toxicity, study withdrawal, or death, whichever comes first.
Patients with metastatic TNBC who are refractory/relapsed after 2 or more prior standard-of-care chemotherapies, including taxanes, for advanced disease. See Eligibility for the complete list of inclusion and exclusion criteria.
10 mg/kg on Days 1 and 8 of 21-day cycles
1 of the following 4 TPC regimens (no combinations are permitted):
Primary outcome measure
Secondary outcome measures
Key entry criteria